15,545 Shares in Precision BioSciences, Inc. (NASDAQ:DTIL) Bought by Samalin Investment Counsel LLC

Samalin Investment Counsel LLC bought a new position in Precision BioSciences, Inc. (NASDAQ:DTIL) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 15,545 shares of the company’s stock, valued at approximately $59,000. Samalin Investment Counsel LLC owned 0.20% of Precision BioSciences as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC purchased a new position in Precision BioSciences in the 4th quarter worth $48,000. Moloney Securities Asset Management LLC boosted its stake in shares of Precision BioSciences by 177.0% during the 4th quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after purchasing an additional 56,100 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Precision BioSciences by 40.7% during the 3rd quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after purchasing an additional 19,088 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Precision BioSciences by 10.9% during the 3rd quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after purchasing an additional 68,943 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Trading Up 1.7 %

Shares of NASDAQ DTIL opened at $5.45 on Monday. Precision BioSciences, Inc. has a 1 year low of $3.61 and a 1 year high of $15.97. The stock has a market cap of $41.81 million, a P/E ratio of 90.85 and a beta of 1.59. The firm has a 50-day moving average of $5.14 and a 200 day moving average of $6.68. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DTIL. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, March 19th. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research note on Friday, January 10th.

Insider Activity at Precision BioSciences

In related news, CEO Michael Amoroso sold 36,838 shares of Precision BioSciences stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the completion of the transaction, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at $500,096.29. This trade represents a 25.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider J. Jefferson Smith sold 10,287 shares of Precision BioSciences stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the transaction, the insider now directly owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This trade represents a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders acquired 8,734 shares of company stock valued at $39,946 and sold 47,279 shares valued at $222,064. 4.00% of the stock is currently owned by corporate insiders.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.